- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00856635
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
January 8, 2018 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON)
The main objective of the study is to determine whether glatiramer acetate 20 mg once daily reduces the amount of axonal loss in the optic nerve after a first event of acute optic neuritis compared to placebo patients and to generate data supporting the potential neuroprotective effect of glatiramer acetate in a human in vivo model of axonal loss.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18 - 45 years
- Isolated, unilateral, first acute optic neuritis (AON) event consistent with inflammatory demyelinization, not explained by other etiologies. Onset of AON is defined by the presentation of visual disturbances.
- Able to provide written informed consent prior to enrollment
- Willing and able to comply with the protocol requirements for the duration of the study
For women of child bearing potential:
- A negative urine pregnancy test o
- Willing to practice an acceptable method of birth control •
- Willing to receive a steroidal regimen
Exclusion Criteria:
- A diagnosis of clinically definite multiple sclerosis (MS) (Clinically Definite Multiple Sclerosis)
- Current use of any approved disease modifying agents for treatment of MS
- Prior clinical episode of optic neuritis in either eye
- Bilateral AON
- Inability to undergo study evaluations in both eyes
- Known ocular or neurological conditions or abnormalities other than refractive error that impair visual function
- Retrogeniculate visual loss
- Refractive error of greater than +6 or -6 diopters
- Neuromyelitis Optica (Devic's disease)
- Systemic diseases that cause inflammatory optic neuropathy, including but not limited to Sarcoidosis, Systemic lupus erythematosus (SLE), Wegener's Granulomatosis, Syphilis, human immunodeficiency virus (HIV)
- Known ocular conditions that preclude dilation
- Any condition that may interfere with performance of Optical Coherence Tomography (OCT): corneal, lens or fundoscopic abnormality, a co-morbid ocular condition not related to optic neuritis as detected on the OCT reading
- Any condition that precludes administration of Glatiramer Acetate, such as a known history of sensitivity to mannitol
- Diabetes Mellitus Types I or II
- Gastric bypass surgery
- Current use of chemotherapy or radiotherapy
- Treatments that may cause visual loss such as plaquenil, anti-tubercular agents, interferon (IFN)-alpha therapy, monoclonal antibodies Cardiac medications that may affect visual evaluations such as digitalis, amiodarone, quinine
- Ongoing treatment with steroids (for longer than 10 days) within the last 3 months
- Significant or unstable medical, systemic, psychiatric or logistical condition that affects the patient's ability to give informed consent or to complete the study procedures
- Use of an investigational drug within 30 days prior to randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glatiramer acetate
Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
|
20 mg injected daily subcutaneously
Other Names:
|
Placebo Comparator: Placebo
Participants received placebo subcutaneous injection once a day for up to 6 months.
|
injected daily subcutaneously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retinal Nerve Fiber Layer Thickness at Baseline and Month 6
Time Frame: Baseline and Month 6
|
Axonal loss in the optic nerve (due to optic neuritis) was assessed by measuring retinal nerve fiber thickness of the affected eye using optical coherence tomography (OCT) at Baseline and Month 6.
|
Baseline and Month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To Evaluate Changes on Additional OCT Parameters and Other Visual Function and Clinical Parameters.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mark J. Kupersmith, MD, Roosevelt hospital
- Principal Investigator: Peter Calabresi, MD, John Hopkins School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
March 4, 2009
First Submitted That Met QC Criteria
March 5, 2009
First Posted (Estimate)
March 6, 2009
Study Record Updates
Last Update Posted (Actual)
February 6, 2018
Last Update Submitted That Met QC Criteria
January 8, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Eye Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Neuritis
- Optic Neuritis
- Physiological Effects of Drugs
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Glatiramer Acetate
- (T,G)-A-L
Other Study ID Numbers
- PM030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Optic Neuritis
-
Medical University of ViennaUnknownOptic; Neuritis, With DemyelinationAustria
-
BiogenCompletedAcute Optic NeuritisSweden, Australia, Italy, Spain, United Kingdom, Germany, Belgium, Denmark, Hungary, Czech Republic, Canada
-
Novartis PharmaceuticalsTerminatedAcute Demylelinating Optic NeuritisUnited States, Spain
-
BiogenCompletedAcute Optic NeuritisSweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
-
Accure TherapeuticsSimbec ResearchCompletedOptic Neuritis | Optic; Neuritis, With DemyelinationUnited Kingdom
-
OculisNeurotrialsRecruitingOptic Neuritis | Optic; Neuritis, With DemyelinationFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of ZurichUniversity Hospital, Zürich; Swiss MS Society; Data Management, Clinical Trials...TerminatedAcute Autoimmune Inflammatory Optic NeuritisSwitzerland
-
Chinese PLA General HospitalRecruiting
-
Xiujuan ZhaoUnknown
Clinical Trials on Glatiramer Acetate
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapse-Remitting Multiple SclerosisUnited States
-
Synthon BVCompletedMultiple SclerosisUnited States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
-
Teva Neuroscience, Inc.CompletedMultiple SclerosisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapsing Remitting Multiple Sclerosis
-
Teva Neuroscience, Inc.Completed
-
Federal University of São PauloUnknownDiabetic RetinopathyBrazil
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapse Remitting Multiple Sclerosis
-
Sheba Medical CenterUnknownMultiple SclerosisIsrael